Thoratec Should Move Ahead on a Sale, Oracle Proposes in Filing

Thoratec Corp. (THOR), a maker of implantable heart pumps, should retain an investment bank to put the company up for sale, according to a shareholder proposal by investor Oracle Investment Management Inc.

The proposal for the next shareholder meeting was disclosed in a regulatory filing today. Oracle, based in Greenwich, Connecticut, controls 5.2 percent of Pleasanton, California- based Thoratec.

Larry Feinberg, Oracle’s founder, earlier this month urged Thoratec’s board to hire a bank to handle an auction of the company. The heart-pump maker may attract bids from Johnson & Johnson (JNJ), Medtronic Inc. (MDT) or Abbott Laboratories (ABT) if the company seeks a buyer, Feinberg said in an interview on Dec. 6.

“We believe that the market clout, capital resources, and relevant experience of a larger and more tenured medtech company is required to accelerate the penetration of this burgeoning market opportunity,” Oracle said in a supporting statement in the filing.

The market for Thoratec’s main product, the left- ventricular assist device, is $5 billion to $10 billion, Oracle said in its statement. A company device in development may generate as much as $1 billion, Oracle said.

Thoratec gained less than 1 percent to $30.71 at 10:16 a.m. New York time.

To contact the reporter on this story: Drew Armstrong in Washington at darmstrong17@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.